Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Total Current Liabilities (2016 - 2025)

International Stem Cell (ISCO) has disclosed Total Current Liabilities for 16 consecutive years, with $4.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities fell 1.34% to $4.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.7 million, a 1.34% decrease, with the full-year FY2024 number at $4.7 million, down 2.98% from a year prior.
  • Total Current Liabilities was $4.7 million for Q3 2025 at International Stem Cell, down from $4.9 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $5.1 million in Q1 2025 to a low of $4.3 million in Q4 2021.
  • A 5-year average of $4.7 million and a median of $4.7 million in 2024 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: surged 188.87% in 2021, then fell 2.98% in 2024.
  • International Stem Cell's Total Current Liabilities stood at $4.3 million in 2021, then increased by 8.19% to $4.6 million in 2022, then increased by 4.25% to $4.8 million in 2023, then dropped by 2.98% to $4.7 million in 2024, then decreased by 0.7% to $4.7 million in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Total Current Liabilities are $4.7 million (Q3 2025), $4.9 million (Q2 2025), and $5.1 million (Q1 2025).